搜索全部
  • 产品中心
  • 专项研究
  • 资料下载
  • 细胞/抗体
免费咨询电话:

400-627-9288

产品中心> 假病毒> 新冠假病毒中和抗体
SARS-CoV-2 Spike(B.1.1.7/VUI-202012/01,del145Y)Pseudotyped Virus (GFP-Luciferase) DATASHEET
用途:中和抗体 类别:其它 研究内容: SARS-CoV-2 载体类型:其他 表达方式:其他 真核抗性:其他 荧光标记:其他
此假病毒产品是以NCBI Reference Sequence: NC_045512.2中的Spike蛋白为假病毒刺突蛋白,具体突变位点为:deletion69-70、deletion144、N501Y、A570D、D614G、P681H、T716I、S982A、D1118H,并基于HIV慢病毒包装体系,构建的将GFP绿色荧光和Luciferase萤火虫荧光素酶基因表达质粒包裹在内的具备感染293T-ACE2细胞能力的复制缺陷型假病毒,可以通过荧光和Luciferase值的测定假病毒感染的能力
货号 规格 价格 储运 加入购物车
GM-0220PV33-96T 96T 询价元优惠价:元 -80℃
GM-0220PV33-480T 480T 询价元优惠价:元 -80℃
GM-0220PV33-960T 960T 询价元优惠价:元 -80℃
在线咨询

描述

S蛋白是冠状病毒最重要的表面膜蛋白,含有S1S2两个亚基。其中S1包含受体结合域(receptorbinding domain RBD),负责识别细胞的受体。S2含有膜融合过程所需的基本元件。研究发现,S蛋白介导受体结合和膜融合,对病毒感染宿主细胞起重要作用,此外,S蛋白上含有刺激中和抗体的主要抗原及细胞毒性淋巴细胞的重要靶标,是疫苗设计、治疗性抗体和诊断方法的关键靶标(Walls et al., 2020; Wang et al., 2020; Zhang et al., 2020)

为避免传统的SARS-CoV-2病毒中和试验需要操作活毒而存在的生物安全隐患,吉满生物建立了基于假病毒系统的操作较安全的SARS-CoV-2中和试验技术平台。本产品以HIV慢病毒载体和SARS-CoV-2 S蛋白为基础,将SARS-CoV-2 S蛋白替换慢病毒包膜蛋白VSVG,与慢病毒包装质粒和CMV-GFP-T2A-Luciferase质粒共转染293T细胞,包装SARS-CoV-2 S假病毒,表面表达SARS-CoV-2 S蛋白,并且同时携带GFP荧光和Luciferase荧光素酶报告基因,可通过观察荧光和检测荧光素酶活性评价假病毒感染细胞的活性,该假病毒无自主复制能力,安全性高。

该突变型假病毒具体突变位点为:deletion69-70、deletion144、N501Y、A570D、D614G、P681H、T716I、S982A、D1118H可用于英国突变型SARS-CoV-2受体药物筛选中和抗体检测疫苗效果评价


效果验证

图1  SARS-CoV-2 Spike S蛋白及突变型假病毒感染HEK293与HEK293T-ACE2荧光图片

图2 SARS-CoV-2 Spike S蛋白(B.1.1.7/VUI-202012/01,del145Y)突变型假病毒感染HEK293T-ACE2测定Luciferase数值


3 SARS-CoV-2 Spike 蛋白(B.1.1.7/VUI-202012/01,del145Y)突变型假病毒中和抗体实验

客户文章

序号 文章名称 发表时间 影响因子 文章链接
1 Intranasal administration of a recombinant RBD vaccine induces long-term immunity against Omicron-included SARS-CoV-2 variants 2022/5/17 38.104 https://www.nature.com/articles/s41392-022-01002-1
2 Inactivated SARS-CoV-2 induces acute respiratory distress syndrome in human ACE2-transgenic mice 2021/12/24 38.1027 https://www.nature.com/articles/s41392-021-00851-6
3 S19W, T27W, and N330Y mutations in ACE2 enhance SARS-CoV-2 S-RBD binding toward both wild-type and antibody-resistant viruses and its molecular basis 2021/9/16 38.1027 https://pubmed.ncbi.nlm.nih.gov/34531369/
4 mRNA Vaccines Against SARS-CoV-2 Variants Delivered by Lipid Nanoparticles Based on Novel Ionizable Lipids 2022/7/19 19.9246 https://onlinelibrary.wiley.com/doi/full/10.1002/adfm.202204692
5 An engineered 5-helix bundle derived from SARS-CoV-2 S2 pre-binds sarbecoviral spike at both serological-and endosomal-pH to inhibit virus entry 2022/6/27 19.5673 https://www.tandfonline.com/doi/full/10.1080/22221751.2022.2095308
6 Inhalable nanovaccine with biomimetic coronavirus structure to trigger mucosal immunity of respiratory tract against COVID-19 2021/3/19 16.744 https://www.sciencedirect.com/science/article/pii/S1385894721009803
7 Peptide Binder with High-Affinity for the SARS-CoV-2 Spike Receptor-Binding Domain 2022/6/17 10.383 https://pubs.acs.org/doi/full/10.1021/acsami.2c03707
8 Magnetic graphene quantum dots facilitate closed-tube one-step detection of SARS-CoV-2 with ultra-low field NMR relaxometry 2021/3/15 9.221 https://www.sciencedirect.com/science/article/pii/S0925400521003555
9 A reduced graphene oxide-Fe3O4 composite functionalized with cetyltrimethylammonium bromide for efficient adsorption of SARS-CoV-2 spike pseudovirus and human enteric viruses 2021/11/9 8.943 https://www.sciencedirect.com/science/article/pii/S0045653521034676
10 A potent neutralizing nanobody targeting the spike receptor-binding domain of SARS-CoV-2 and the structural basis of its intimate binding 2022/5/18 8.786 https://www.frontiersin.org/articles/10.3389/fimmu.2022.820336/pdf
11 MPLA-Adjuvanted Liposomes Encapsulating S-Trimer or RBD or S1, but Not S-ECD, Elicit Robust Neutralization Against SARS-CoV-2 and Variants of Concern 2022/2/2 8.039 https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.1c02025
12 Self-Adjuvanting Lipoprotein Conjugate αGalCer-RBD Induces Potent Immunity against SARS-CoV-2 and its Variants of Concern 2022/1/24 8.039 https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.1c02000
13 Synthetic Neutralizing Peptides Inhibit the Host Cell Binding of Spike Protein and Block Infection of SARS-CoV-2 2021/9/17 8.0385 https://pubs.acs.org/doi/abs/10.1021/acs.jmedchem.1c01440
14 Potential drug discovery for COVID-19 treatment targeting Cathepsin L using a deep learning-based strategy 2022/5/17 6.155 https://www.sciencedirect.com/science/article/pii/S2001037022001799

相关产品

登录

还没有帐号 注册

注册

<返回登录